← Leaderboards
Mary R Galinski
Emory University
$18,988,233
Attributed
$18,988,233
Total exposure
42
Grants
27
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.3M · FY2005–12$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$18,988,233 · 42
By mechanism
R01$9,215,293 · 4
P01$3,430,075 · 1
N01$3,389,290 · 1
P51$1,563,075 · 33
R21$1,390,500 · 3
Top collaborators
No co-investigators on record.
Most similar at Emory University
Same institution · by research overlap
- Alberto Moreno$7,414,543
- Dean P. Jones$29,823,845
- Tracey Jane Lamb$8,710,457
Others in their field
Top investigators on “Malaria”
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$82,291,297
- Stephen Lev Hoffman · Sanaria, Inc.$79,440,588
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$61,561,099
Research focus
MalariaPlasmodiumMacaca MulattaInfectionProteinsErythrocytesBloodMalaria VaccinesResourcesIn VitroPrimatesImmune ResponseMolecularNonhuman PrimateInvestigationVaccinesBaseBiologicalAntigensFundingCellsParasitesStagingResearch Personnel
Grant awards (72)
Integrated Approach to Host-Pathogen Interactions$3,389,290
N01 · FY2012 · AI · contact PI
Molecular Analysis of Plasmodium vivax Surface Antigens$548,764
R01 · FY2012 · AI · contact PI
Plasmodium cynomolgi as a model for P. vivax.$176,000
R21 · FY2012 · AI · contact PI
RBL Binding Domain Malaria Candidate Vaccines$176,000
R21 · FY2012 · AI · contact PI
Molecular Analysis of Plasmodium vivax Surface Antigens$549,027
R01 · FY2011 · AI · contact PI
RBL Binding Domain Malaria Candidate Vaccines$308,000
R21 · FY2011 · AI · contact PI
Plasmodium cynomolgi as a model for P. vivax.$308,000
R21 · FY2011 · AI · contact PI
MOLECULAR BASIS OF ANTIGENIC VARIATION ON MALARIA$41,159
P51 · FY2011 · RR · contact PI
RETICULOCYTE BINDING-LIKE (RBL) PROTEINS AS NEW GENERATION MALARIA VACCINES$41,159
P51 · FY2011 · RR · contact PI
MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENS$41,159
P51 · FY2011 · RR · contact PI
Molecular Analysis of Plasmodium vivax Surface Antigens$554,555
R01 · FY2010 · AI · contact PI
Molecular Mechanisms of Antigenic Variation in Malaria$398,429
R01 · FY2010 · AI · contact PI
PLASMODIUM VIVAX MSP-3 AND MSP-9 AS VACCINE IMMUNOGENS$54,827
P51 · FY2010 · RR · contact PI
MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENS$54,827
P51 · FY2010 · RR · contact PI
MOLECULAR BASIS OF ANTIGENIC VARIATION ON MALARIA$54,827
P51 · FY2010 · RR · contact PI
RETICULOCYTE BINDING-LIKE (RBL) PROTEINS AS NEW GENERATION MALARIA VACCINES$54,827
P51 · FY2010 · RR · contact PI
Molecular Analysis of Plasmodium vivax Surface Antigens$543,840
R01 · FY2009 · AI · contact PI
Molecular Mechanisms of Antigenic Variation in Malaria$402,453
R01 · FY2009 · AI · contact PI
MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENS$54,800
P51 · FY2009 · RR · contact PI
PLASMODIUM VIVAX MSP-3 AND MSP-9 AS VACCINE IMMUNOGENS$54,800
P51 · FY2009 · RR · contact PI
MOLECULAR BASIS OF ANTIGENIC VARIATION ON MALARIA$54,800
P51 · FY2009 · RR · contact PI
Non-human primate models of malarial anemia$825,798
P01 · FY2008 · HL · contact PI
Non-human primate models of malarial anemia$786,544
P01 · FY2008 · HL · contact PI
Molecular Analysis of Plasmodium vivax Surface Antigens$528,000
R01 · FY2008 · AI · contact PI
Molecular Mechanisms of Antigenic Variation in Malaria$402,453
R01 · FY2008 · AI · contact PI
MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENS$35,600
P51 · FY2008 · RR · contact PI
PLASMODIUM VIVAX MSP-3 AND MSP-9 AS VACCINE IMMUNOGENS$35,600
P51 · FY2008 · RR · contact PI
MOLECULAR BASIS OF ANTIGENIC VARIATION ON MALARIA$35,600
P51 · FY2008 · RR · contact PI
Non-human primate models of malarial anemia$779,966
P01 · FY2007 · HL · contact PI
Molecular Mechanisms of Antigenic Variation in Malaria$410,248
R01 · FY2007 · AI · contact PI
PLASMODIUM VIVAX MSP-3 AND MSP-9 AS VACCINE IMMUNOGENES$400,606
R01 · FY2007 · AI · contact PI
MOLECULAR BASIS OF ANTIGENIC VARIATION ON MALARIA$39,497
P51 · FY2007 · RR · contact PI
PLASMODIUM VIVAX MSP-3 AND MSP-9 AS VACCINE IMMUNOGENS$39,497
P51 · FY2007 · RR · contact PI
MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENS$39,497
P51 · FY2007 · RR · contact PI
Non-human primate models of malarial anemia$526,552
P01 · FY2006 · HL · contact PI
Molecular Mechanisms of Antigenic Variation in Malaria$422,500
R01 · FY2006 · AI · contact PI
PLASMODIUM VIVAX MSP-3 AND MSP-9 AS VACCINE IMMUNOGENES$387,571
R01 · FY2006 · AI · contact PI
PLASMODIUM VIVAX MSP-3 AND MSP-9 AS VACCINE IMMUNOGENS$40,116
P51 · FY2006 · RR · contact PI
MOLECULAR BASIS OF ANTIGENIC VARIATION ON MALARIA$40,116
P51 · FY2006 · RR · contact PI
MALARIA VACCINE INITIATIVE TRIAL #2$40,116
P51 · FY2006 · RR · contact PI
MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENS$40,116
P51 · FY2006 · RR · contact PI
Non-human primate models of malarial anemia$511,215
P01 · FY2005 · HL
PLASMODIUM VIVAX MSP-3 AND MSP-9 AS VACCINE IMMUNOGENES$397,500
R01 · FY2005 · AI
MALARIA VACCINE INITIATIVE TRIAL #2$32,021
P51 · FY2005 · RR
MOLECULAR ANALYSIS OF ANTIGENIC VARIATION IN MALARIA$30,784
P51 · FY2005 · RR
VALIDATION OF UNIVERSAL T CELL EPITOPE APPROACH AS PREDICTOR FOR VACCINES$30,784
P51 · FY2005 · RR
EMORY NAVY MALARIA VACCINE TRIAL #2$30,784
P51 · FY2005 · RR
MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENS$30,784
P51 · FY2005 · RR
PLASMODIUM VIVAX MSP-3 AND MSP-9 AS VACCINE IMMUNOGENS$30,784
P51 · FY2005 · RR
MOLECULAR BASIS OF ANTIGENIC VARIATION ON MALARIA$25,835
P51 · FY2005 · RR
Molecular Analysis of Plasmodium vivax Surface Antigens$645,851
R01 · FY2004 · AI
Molecular Analysis of Antigenic Variation in Malaria$422,500
R21 · FY2004 · AI
PLASMODIUM VIVAX MSP-3 AND MSP-9 AS VACCINE IMMUNOGENES$422,500
R01 · FY2004 · AI
MALARIA VACCINE INITIATIVE TRIAL #2$35,765
P51 · FY2004 · RR
VALIDATION OF UNIVERSAL T CELL EPITOPE APPROACH$34,361
P51 · FY2004 · RR
EMORY NAVY MALARIA VACCINE TRIAL #2$34,361
P51 · FY2004 · RR
MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENS$34,361
P51 · FY2004 · RR
MOLECULAR BASIS OF ANTIGENIC VARIATION ON MALARIA$28,909
P51 · FY2004 · RR
Molecular Analysis of Plasmodium vivax Surface Antigens$627,055
R01 · FY2003 · AI
MALARIA VACCINE INITIATIVE TRIAL #2$31,173
P51 · FY2003 · RR
VALIDATION OF UNVIERSAL T CELL EPITOPE APPROACH AS PREDICTOR FOR VACCINES$31,173
P51 · FY2003 · RR
MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENS$29,977
P51 · FY2003 · RR
EMORY NAVY MALARIA VACCINE TRIAL #2$29,977
P51 · FY2003 · RR
MOLECULAR BASIS OF ANTIGENIC VARIATION ON MALARIA$25,193
P51 · FY2003 · RR
NOVEL LINEAR PEPTIDE UNIVERSALL MALARIA VACCINES$23,997
P51 · FY2003 · RR
Molecular Analysis of Plasmodium vivax Surface Antigens$486,890
R01 · FY2002 · AI
Molecular Analysis of Plasmodium vivax Surface Antigens$388,518
R01 · FY2001 · AI
MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENS$358,549
R01 · FY2000 · AI
MOLECULAR ANALYSIS OF ANTIGENIC VARIATION IN MALARIA$339,984
R01 · FY2000 · AI
MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENS$39,712
P51 · FY2000 · RR
PLASMODIUM KNOWLESI TETRAVALENT DNA VACCINE$39,712
P51 · FY2000 · RR
MOLECULAR ANALYSIS OF ANTIGENIC VARIATION IN PLASMODIUM$39,688
P51 · FY2000 · RR